Israel Englander Atai Life Sciences N.V. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Millennium Management LLC holds 1,135,752 shares of ATAI stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,135,752

Previous 981,557 15.71%

Holding current value

$1.85 Million

Previous $1.31 Million 18.31%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.33 - $2.55 $205,079 - $393,197	154,195 Added 15.71%	1,135,752 $1.54 Million
Q4 2024 Feb 14, 2025	BUY	$1.06 - $1.78 $572,219 - $960,897	539,830 Added 122.21%	981,557 $1.31 Million
Q3 2024 Nov 14, 2024	SELL	$1.16 - $1.64 $239,492 - $338,592	-206,459 Reduced 31.85%	441,727 $512,000
Q2 2024 Aug 14, 2024	SELL	$1.27 - $2.6 $1.99 Million - $4.08 Million	-1,568,334 Reduced 70.76%	648,186 $862,000
Q1 2024 May 15, 2024	BUY	$1.5 - $2.19 $2.18 Million - $3.19 Million	1,455,764 Added 191.36%	2,216,520 $4.37 Million
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $361,284 - $538,452	-347,389 Reduced 31.35%	760,756 $1.07 Million
Q2 2023 Aug 14, 2023	BUY	$1.44 - $2.19 $539,040 - $819,791	374,334 Added 51.01%	1,108,145 $1.91 Million
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $592,882 - $1.37 Million	-506,737 Reduced 40.85%	733,811 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $809,545 - $1.21 Million	340,145 Added 37.78%	1,240,548 $3.3 Million
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $2.19 Million - $3.4 Million	697,624 Added 344.03%	900,403 $2.98 Million

Others Institutions Holding ATAI

# of Institutions

Shares Held

23.7M

Call Options Held

351K

Put Options Held

170K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $270M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account